SeaStar Medical (ICU) announces that Stanford Medicine is cleared to actively enroll subjects in the NEUTRALIZE-AKI pivotal trial. With the recent addition of two Department of Defense medical centers, 12 sites are now activated to enroll subjects in the trial with enrollment at 52. “It goes without saying that Stanford is an incredibly important site,” said Kevin Chung, MD, Chief Medical Officer of SeaStar Medical. “The recent decision by the U.S. Centers for Medicare and Medicaid Services to reimburse certain expenses for Medicare patients enrolled in this trial is proving critical in recruiting new medical sites. We are delighted that Stanford will be working with us to help change the standard of care for our most critically ill patients.”
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See the top stocks recommended by analysts >>
Read More on ICU:
- SeaStar Medical to distribute QUELIMMUNE directly to hospital customers
- SeaStar announces enrollment in NEURTALIZE-AKI trial passes halfway point
- SeaStar Medical announces presentation of new data on SCD at ASN 2024
- SeaStar expands NEUTRALIZE-AKI trial with two military medical facilities
- SeaStar Medical reports enrollment momentum in adult AKI trial
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
